rilzabrutinib
Nervous system (NOT)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
biotech · Immune Thrombocytopenia
Principia Biopharma
Principia Biopharma, a Sanofi Company
Principia Biopharma drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
South San Francisco, USA HQ
2008 Founded
16 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2008
- Employees
- 16
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Principia Biopharma pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Principia Biopharma drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.